Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFx-Hu2.0 in skin cancer
NCT04925713Phase 1Completed
- Sponsor
- TuHURA Biosciences, Inc.
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IFx-Hu2.0 in cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC) and cutaneous melanoma (CM), sponsored by TuHURA Biosciences, Inc. Primary endpoints: Rate of Adverse Events at 28 days and Number of Patients Who Completed the Trial at 28 days. Started Jun 2021; status: completed.
02
Drugs
IFx-Hu2.0
03
Conditions
cutaneous squamous cell carcinoma (cSCC)basal cell carcinoma (BCC)cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT04925713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925713.